GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2012

NIH’s NCATS Establishes $20M Collaborative Drug Repositioning Initiative

  • NIH’s new National Center for Advancing Translational Sciences (NCATS) has launched an initiative through which pharma companies’ sidelined drug candidates will be developed for new potential indications in partnership with academic researchers. The Discovering New Therapeutic Uses for Existing Molecules Initiative will focus on compounds that have already negotiated key steps in development, including safety testing in humans. Pfizer, AstraZeneca, and Eli Lilly have already signed up as NCATS partners, and have agreed to make dozens of compounds available for the pilot phase of the initiative.

    The pilot phase of the initiative will have at its disposal about $20 million in fiscal 2013 to support preclinical and clinical feasibility studies on about 20 compounds from industry collaborators. The funding will be awarded to support two- to three-year staged, cooperative agreement research grants. Under the awards researchers will conduct preclinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to evaluate whether a compound is effective against a previously unexplored disease target.

    "Clearly, we need to speed the pace at which we are turning discoveries into better health outcomes," comments NIH director Francis S. Collins, M.D. “NIH looks forward to working with our partners in industry and academia to tackle an urgent need that is beyond the scope of any one organization or sector."

    NCATS was established at the end of 2011 to promote and catalyze the development of new therapeutics and diagnostics across a range of disease areas. In addition to the newly launched drug repositioning initiative, NCAT also coordinates the Clinical and Translational Science Awards program, which promotes the development of translational medicine infrastructure, skills, and networking capabilities. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »